Predictive factors for decreased baseline quality of life in patients with sinonasal malignancies

Fleseriu, Cara M.; Beswick, Daniel M.; Maoz, Sabrina L.; Hwang, Peter H.; Choby, Garret; Kuan, Edward C.; Chan, Erik P.; Adappa, Nithin D.; Geltzeiler, Mathew; Getz, Anne E.; Humphries, Ian M.; Le, Christopher H.; Abuzeid, Waleed M.; Chang, Eugene H.; Jafari, Aria; Kingdom, Todd T.; Kohanski, Michael A.; Lee, Jivianne K.; Nabavizadeh, Seyed A.; Nayak, Jayakar V.; Palmer, James N.; Patel, Zara M.; Pinheiro‐Neto, Carlos D.; Resnick, Adam C.; Smith, Timothy L.; Snyderman, Carl H.; St. John, Maie A.; Storm, Jay; Suh, Jeffrey D.; Wang, Marilene B.; Wang, Eric W.

doi:10.1002/alr.23261

Cited by 8 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our group's recent report, patients with SNM presented with globally worsened sinonasal QOL at baseline. 20,39 SNOT-22 scores were elevated at the time of diagnosis, but improved gradually over the post-treatment period, surpassing the MCID threshold of −8.9 between 2 and 5 years after baseline. 20,39 In the present study of sinonasal subdomain QOL, we observed that the reductions in sinonasal QOL were primarily attributable to improvements in rhinologic, extra-nasal, sleep and psychological subdomains.…”

Section: Discussionmentioning

confidence: 91%

“…20,39 SNOT-22 scores were elevated at the time of diagnosis, but improved gradually over the post-treatment period, surpassing the MCID threshold of −8.9 between 2 and 5 years after baseline. 20,39 In the present study of sinonasal subdomain QOL, we observed that the reductions in sinonasal QOL were primarily attributable to improvements in rhinologic, extra-nasal, sleep and psychological subdomains. On subanalysis of our cohort of patients with complete follow-up data (the "Complete" subcohort), both the rhinologic and extra-nasal subdomains showed statistically significant improvement but fell short of MCID thresholds.…”

Section: Discussionmentioning

confidence: 91%

See 1 more Smart Citation

SNOT‐22 subdomain outcomes following treatment for sinonasal malignancy: A prospective, multicenter study

Grimm,

Beswick,

Maoz

et al. 2024

Int Forum Allergy Rhinol

Self Cite

View full text Add to dashboard Cite

BackgroundPatients with sinonasal malignancy (SNM) present with significant sinonasal quality of life (QOL) impairment. Global sinonasal QOL as measured by the 22‐item Sinonasal Outcomes Test (SNOT‐22) has been shown to improve with treatment. This study aims to characterize SNOT‐22 subdomain outcomes in SNM.MethodsPatients diagnosed with SNM were prospectively enrolled in a multi‐center patient registry. SNOT‐22 scores were collected at the time of diagnosis and through the post‐treatment period for up to 5 years. Multivariable regression analysis was used to identify drivers of variation in SNOT‐22 subdomains.ResultsNote that 234 patients were reviewed, with a mean follow‐up of 22 months (3 months–64 months). Rhinologic, psychological, and sleep subdomains significantly improved versus baseline (all p < 0.05). Subanalysis of 40 patients with follow‐up at all timepoints showed statistically significant improvement in rhinologic, extra‐nasal, psychological, and sleep subdomains, with minimal clinically important difference met between 2 and 5 years in sleep and psychological subdomains. Adjuvant chemoradiation was associated with worse outcomes in rhinologic (adjusted odds ratio (5.22 [1.69–8.66])), extra‐nasal (2.21 [0.22–4.17]) and ear/facial (5.53 [2.10–8.91]) subdomains. Pterygopalatine fossa involvement was associated with worse outcomes in rhinologic (3.22 [0.54–5.93]) and ear/facial (2.97 [0.32–5.65]) subdomains. Positive margins (5.74 [2.17–9.29]) and surgical approach—combined versus endoscopic (3.41 [0.78–6.05])—were associated with worse psychological outcomes. Adjuvant radiation (2.28 [0.18–4.40]) was associated with worse sleep outcomes.ConclusionsSinonasal QOL improvements associated with treatment of SNM are driven by rhinologic, extra‐nasal, psychological, and sleep subdomains.

show abstract

Section: Discussionmentioning

confidence: 91%

Section: Discussionmentioning

confidence: 91%

SNOT‐22 subdomain outcomes following treatment for sinonasal malignancy: A prospective, multicenter study

Grimm,

Beswick,

Maoz

et al. 2024

Int Forum Allergy Rhinol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Two recent studies also identified gender differences in QoL after skull base surgery. 9,10 The first study by Buchlak et al in 2022 found that low preoperative QoL is negatively associated with female gender in endoscopic pituitary surgery using the anterior skull base surgery (ASBS) questionnaire. Another study by Fleseriu et al in 2023 also found worse baseline rhinologic QoL in female patients using the SNOT-22 rhinologic domain in patients with sinonasal malignancy.…”

Section: Discussionmentioning

confidence: 99%

Gender Differences in Quality-of-Life Outcome in Patients Undergoing Endoscopic Endonasal Skull Base Surgery

Tumlin,

Al-Asadi,

Turner

et al. 2023

J Neurol Surg B Skull Base

View full text Add to dashboard Cite

Background Prior studies showed that female patients with chronic rhinosinusitis (CRS) suffer a worse disease-specific quality of life (QoL). Goal The aim of this study is to investigate gender differences in sinonasal QoL outcomes in patients requiring endoscopic endonasal skull base surgeries (EESBS). Methods Cross-sectional analysis of patients presenting to our clinic from August 2020 to December 2022 with skull base tumors, spontaneous cerebrospinal fluid (CSF) rhinorrhea, or Grave's orbitopathy (for orbital decompression) was performed. Baseline and postsurgical QoL were measured using the 22-item Sinonasal Outcome Test (SNOT-22). Patients' demographics and comorbidities were reviewed. Patients with concomitant CRS were excluded. Results Eighty-six patients were included (54 with skull base tumors, 17 Grave's orbitopathy, and 15 spontaneous CSF rhinorrhea). The mean age of the patients was 52 years (range: 12.4–81.5 years), and 51.6% of the patients were females. There was no age difference between female and male patients. Smoking history, asthma, and allergic rhinitis were also similar between the two groups. Female patients had a significantly higher incidence of depression (58.3 vs. 32.4%, p = 0.018) and migraine (50.0 vs. 21.6%, p = 0.007). Female patients had a significantly worse overall SNOT-22 scores at baseline (33.6 vs. 18.2, p = 0.001), at the 3-month follow-up (29.7 vs. 15.5, p = 0.002), and at the 6-month follow-up (33.5 vs. 14.9, p = 0.005). This worse QoL was seen mainly in the ear/facial, sleep, and psychological domains. Linear regression of the SNOT-22 scores and its subdomains adjusting for comorbidities showed that migraine was found to be the most significant determinant of gender differences in the QoL. Conclusion Female patients who undergo EESBS show higher overall SNOT-22 scores secondary to higher incidence of migraine.

show abstract

“…8 However, OE carries significant morbidity and decreased quality of life. [9][10][11] Recently, multimodal therapies to achieve improved survival without OE has been investigated. One approach is the use of induction chemotherapy (IC), a promising treatment modality that may allow for OP treatment without compromising patient oncologic outcomes.…”

Section: Introductionmentioning

confidence: 99%

The role of induction chemotherapy for orbital invasion in sinonasal malignancies: A systematic review

Tang,

Calcaterra,

Harris

et al. 2024

Int Forum Allergy Rhinol

Self Cite

View full text Add to dashboard Cite

BackgroundSinonasal malignancies (SNMs) frequently present with orbital invasion. Orbital exenteration (OE) can lead to significant morbidity. Induction chemotherapy (IC) is a promising treatment alternative that may allow for orbit preserving (OP) treatments without compromising patient survival. This systematic review was conducted to synthesize the published data on SNM patients with orbital invasion who underwent IC, including tumor response, orbital outcomes, and survival.MethodsThe study protocol was designed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis guidelines. Databases Embase, Cochrane, Medline, and Scopus, from inception to July 17, 2023, were searched.ResultsNineteen studies were included, encompassing 305 SNM patients with orbital invasion treated with IC. Fourteen studies reported an overall IC response rate (positive response defined as complete or partial tumor volume reduction) of 77.2%. Among included studies, OE rates after IC ranged from 0 to 40%. Three studies reported a high rate of posttreatment functional orbital preservation (89.8–96.0%). Five studies specifically reported that 62.5% (60 out of 96) of patients were downgraded from planned OE to OP treatment following IC. Three studies reported a significant overall survival (OS) improvement in IC responders versus IC nonresponders. Following IC, 5‐year OS ranged from 44.2 to 55.5%. Patients with olfactory neuroblastoma demonstrated the highest IC response rate and lowest OE rate (100 and 0%, respectively) versus those with sinonasal undifferentiated carcinomas (68.4 and 0%) or squamous cell carcinomas (76.7 and 16%).ConclusionsFor select patients, IC may allow for OP in locally advanced SNMs with orbital involvement.

show abstract

Predictive factors for decreased baseline quality of life in patients with sinonasal malignancies

Cited by 8 publications

References 22 publications

SNOT‐22 subdomain outcomes following treatment for sinonasal malignancy: A prospective, multicenter study

SNOT‐22 subdomain outcomes following treatment for sinonasal malignancy: A prospective, multicenter study

Gender Differences in Quality-of-Life Outcome in Patients Undergoing Endoscopic Endonasal Skull Base Surgery

The role of induction chemotherapy for orbital invasion in sinonasal malignancies: A systematic review

Contact Info

Product

Resources

About